Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 15.40

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet (2009) 13.51

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet (2005) 7.09

Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med (2005) 6.72

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57

Meta-analysis of Pap test accuracy. Am J Epidemiol (1995) 4.49

Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA (2001) 4.26

Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care (1998) 4.04

Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst (1999) 3.88

Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA (2001) 3.26

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet (2014) 2.73

HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev (2008) 2.57

Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis (2001) 2.51

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42

Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol (1998) 2.37

HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol (2006) 2.03

Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J Cancer (2006) 1.94

Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics (2009) 1.92

Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst (2003) 1.84

Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women's interagency HIV study. J Acquir Immune Defic Syndr (2001) 1.78

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin (2011) 1.65

The distribution of sexually-transmitted Human Papillomaviruses in HIV positive and negative patients in Zambia, Africa. BMC Infect Dis (2007) 1.36

Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis (2009) 1.35

The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer (2010) 1.32

Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort. AIDS (2011) 1.32

Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine (2013) 1.31

The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs (2012) 1.30

Contribution of HIV infection to mortality among cancer patients in Uganda. AIDS (2013) 1.19

Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec (2014) 1.12

Invasive cervical cancer and human immunodeficiency virus (HIV) infection: a South African perspective. Int J Gynecol Cancer (2001) 1.06

Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa. J Int AIDS Soc (2012) 1.05

Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis (2013) 1.05

Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine (2008) 1.03

Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine (2013) 1.02

The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study. Cost Eff Resour Alloc (2010) 1.02

Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol Oncol (2008) 0.98

Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis. Sex Transm Infect (2013) 0.97

Oncogenic human papillomavirus DNA loads in human immunodeficiency virus-positive women with high-grade cervical lesions are strongly elevated. J Clin Microbiol (2003) 0.95

The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine (2009) 0.91

Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. Int J Cancer (2005) 0.87

Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa. Vaccine (2013) 0.86

Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine (2013) 0.82

Model-based estimates of long-term persistence of induced HPV antibodies: a flexible subject-specific approach. J Biopharm Stat (2013) 0.79

Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy? BMC Infect Dis (2015) 0.75